Language

English

Publication Date

1-1-2025

Journal

Antimicrobial Stewardship & Healthcare Epidemiology

DOI

10.1017/ash.2025.10057

PMID

40697884

PMCID

PMC12281228

PubMedCentral® Posted Date

7-17-2025

PubMedCentral® Full Text Version

Post-print

Abstract

We examine the performance of microbial cell-free DNA (mcfDNA) next-generation sequencing (NGS) testing on patients admitted to a quaternary care hospital in Houston, Texas. The test was 75.0% sensitive and 97.8% specific for all mycobacterial infections. mcfDNA NGS results led to adjustments in antimicrobial therapy for seven of nine patients with positive results.

Published Open-Access

yes

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.